integrin αvβ3 antagonist cilengitide 268  (MedChemExpress)

Journal: Cell Transplantation

Article Title: Osteopontin Promotes Trophoblast Invasion in the Smooth Muscle Cell-Endothelial Co-Culture At Least Via Targeting Integrin αvβ3

doi: 10.1177/0963689720965979

Figure Lengend Snippet: CGT attenuates the enhanced effects of OPN treatment on the HTR-8 cell invasion. HTR-8 cells (1 × 10 5 cells) were treated with OPN (50 µg/ml) for 24 h, or the HTR-8 cells (1 × 10 5 cells) were co-treated with OPN (50 µg/ml) + CGT (20 µg/ml) for 24 h; after that, GFP-HTR-8 cells were seeded on transwell inserts with polycarbonate filters precoated with Matrigel, the number of invaded GFP-HTR-8 cells were assessed at 24 h after seeding. Magnification = 200×. N = 3; ** P < 0.01 indicated the significant differences between different treatment groups. CGT: cilengitide; GFP: green fluorescent protein; OPN: osteopontin;

Article Snippet: For the cilengitide (CGT; an integrin αvβ3 inhibitor; Sigma-Aldrich) treatment, HTR-8/SVneo cells were incubated with CGT (20 µg/ml) for 24 h before further in vitro assays.

Techniques:

Journal: Cell Transplantation

Article Title: Osteopontin Promotes Trophoblast Invasion in the Smooth Muscle Cell-Endothelial Co-Culture At Least Via Targeting Integrin αvβ3

doi: 10.1177/0963689720965979

Figure Lengend Snippet: CGT attenuates the enhanced effects of OPN treatment on the HTR-8 cell invasion in the SMC-EC co-culturing system. HTR-8 cells (1 × 10 5 cells) were treated with OPN for 24 h, or the HTR-8 cells (1 × 10 5 cells) were first co-treated with OPN + CGT for 24 h; after that, GFP-HTR-8 cells were seeded on the SMC-EC co-culture membrane, and the cell invasive capacity of HTR-8 cells was evaluated under a fluorescent microscope at 72 h after seeding. Magnification = 200×. N = 3; ** P < 0.01 indicated the significant differences between different treatment groups. EC: endothelial cell; CGT: cilengitide; GFP: green fluorescence protein; OPN: osteopontin; SMC: smooth muscle cell.

Article Snippet: For the cilengitide (CGT; an integrin αvβ3 inhibitor; Sigma-Aldrich) treatment, HTR-8/SVneo cells were incubated with CGT (20 µg/ml) for 24 h before further in vitro assays.

Techniques: Co-Culture Assay, Microscopy, Fluorescence

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of integrin ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of anti-α4β1 antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Integrin αvβ3 inhibitor Cilengitide (a cyclic RGD) was obtained from Selleck Chemicals.

Techniques: Blocking Assay, Control, Cell Culture, Expressing, Fluorescence

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) Confocal images of day 4 B cells from 2D co-cultures or 3D immune tissues functionalized with a specific peptide (REDV, RGD, or RDG). Cells were stained for IgM BCR and integrin β subunits on the surface of CD19 + B cells. Scale bar 5 μm. In all studies, immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. B) Schematic showing the BCR crosslinking inside the immune tissues with anti-IgM antibody as an antigen mimic. C) GL7 surface expression level in GL7+ CD19+ GC-like B cells with/without BCR crosslinking and specific integrin ligands. D-F) pBTK, pSYK, and pERK intracellular expression level (normalized to untreated control group in RGD) in CD19 + B cells. In all studies, anti-IgM concentration was either 0 μ μg/mL (indicated as −) or 5 μ μg/mL (indicated as +). Experiments were done with n = 5–7, presented as mean ± standard error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001). Statistical tests were performed using 1-way ANOVA with Tukey’s correction.

Article Snippet: Integrin αvβ3 inhibitor Cilengitide (a cyclic RGD) was obtained from Selleck Chemicals.

Techniques: Staining, Cell Culture, Expressing, Control, Concentration Assay

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) BCL6 intracellular expression level in GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. B) The percentage of EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. C) EZH2 intracellular expression level (normalized to untreated control group) in EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. D-E) IRF4 intracellular expression level and CD138 expression level in immune tissue-derived B cells. In all studies, anti-IgM concentration was either 0 μg/mL (indicated as −) or 5 μg/mL (indicated as +). Experiments were done with N = 5–7, presented as Mean ± Standard Error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001, *P < 0.05). Statistical tests were performed using unpaired student t-test for (E) and 1-way ANOVA with Tukey’s correction for (A–D).

Article Snippet: Integrin αvβ3 inhibitor Cilengitide (a cyclic RGD) was obtained from Selleck Chemicals.

Techniques: Expressing, Control, Derivative Assay, Concentration Assay